Vcanbio Cell & Gene Engineering has led a funding round of undisclosed size for the China-based oncology genomics technology developer.
China-based cancer genomics company Genetron Health has secured an undisclosed sum in a series B round led by biotechnology company Vcanbio Cell & Gene Engineering, China Money Network reported on Tuesday.
The round is reportedly worth several hundred renminbi (RMB100m = $15m) and also featured New Horizon Capital, Shenzhen Share Capital Partners, Yueyin Ventures and unnamed additional backers.
Founded in 2013, Genetron is working on precision healthcare products that use genetic testing technology to detect, prevent and treat cancer. The…
